Serenoa Repens-Lycopene-Selenium and Epilobium-Palmitoylethanolamide-Calendula after transperineal prostate biopsy: a tertiary single center experience

Zaurito P, Scilipoti P, Stabile A, Quarta L, Viti A, Santangelo A, Cosenza A, Brancaccio M, Occhi A, Galdieri A, Porzi ME, Longoni M, Scuderi S, Barletta F, Gandaglia G, Briganti A, Montorsi F. World J Urol. 2026;44(1):422.

Observational studyHumansWith Epilobium and Calendula (with or without a saw palmetto, lycopene and selenium product)

This study tested palmitoylethanolamide together with Epilobium and Calendula (with or without a saw palmetto, lycopene and selenium product). Its results cannot be assigned to palmitoylethanolamide alone. More combination studies.

Design: Observational study
Subjects: 623 men having transperineal prostate biopsy at one Milan hospital, 2023 to 2025, treated or untreated after biopsy
Dose used in the study: A saw palmetto, lycopene and selenium product, with or without an Epilobium, palmitoylethanolamide and Calendula product; doses not in the abstract
Duration: Assessed at 1 week and 1 month
What was measured: International Prostate Symptom Score and International Index of Erectile Function, with subgroup analysis by baseline severity, in 623 patients after transperineal prostate biopsy.

What the authors reported

The study found:

Baseline symptom scores did not differ between treated and untreated men.
Between a third and a half of treated men stopped the products within a month: 34 percent with mild symptoms versus 49 to 51 percent with moderate or severe symptoms (p < 0.001).
In men with mild symptoms before biopsy, treatment was associated with lower odds of a worse symptom score at one week (odds ratio 0.23, 95 percent CI 0.10 to 0.54, p = 0.01).
No effect on erectile function recovery.

Limits of this study

Retrospective, not randomised; patients either received a post-biopsy treatment or none. Two multi-ingredient products, so nothing can be assigned to palmitoylethanolamide. The positive finding is a subgroup result at one week; the authors call it hypothesis-generating. Authors declare no conflicts.

Source

PubMed 42287322 · doi:10.1007/s00345-026-06528-5

Entry checked against the abstract on PubMed on 2026-10-19. The dose shown is the dose the researchers used. It is not a recommendation. How to read this page.